Harms From Haloperidol for Symptom Management in Palliative Care: a Post Hoc Pooled Analysis of Three Randomized Controlled Studies and Two Consecutive Cohort Studies

Hiromichi Matsuoka, Meera Agar, Zac Vandersman, Philip Good, Belinda Fazekas, Linda Brown, Janet Hardy, Jennifer Weil, David Christopher Currow

Research output: Contribution to journalLetter

1 Citation (Scopus)

Abstract

Introduction
Symptom control for people with cancer improves quality of life. Haloperidol is a key drug in palliative care and is frequently used for the treatment of delirium, nausea, and vomiting.1 Haloperidol, a butyrophenone, is a more potent D2 receptor antagonist than other antiemetics, such as prochlorperazine, olanzapine, or chlorpromazine.
Original languageEnglish
Pages (from-to)e6-e8
Number of pages3
JournalJournal of Pain and Symptom Management
Volume58
Issue number3
DOIs
Publication statusPublished - 3 Sep 2019
Externally publishedYes

Keywords

  • cancer
  • haloperidol
  • palliative care

Fingerprint Dive into the research topics of 'Harms From Haloperidol for Symptom Management in Palliative Care: a Post Hoc Pooled Analysis of Three Randomized Controlled Studies and Two Consecutive Cohort Studies'. Together they form a unique fingerprint.

  • Cite this